tamoxifen + triptorelin

Tamoxifen + triptorelin is a combination therapy used primarily as adjuvant endocrine treatment for premenopausal women with hormone receptor-positive, early-stage breast cancer at high risk of recurrence. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks the effects of estrogen on breast tissue, while triptorelin is a gonadotropin-releasing hormone agonist (GnRHa) that suppresses ovarian function and reduces circulating estrogen levels. The combination aims to maximize estrogen suppression by both blocking its action and reducing its production, thereby inhibiting the growth of hormone-sensitive breast cancer cells. This regimen has been shown to improve disease control and survival in certain high-risk populations compared to tamoxifen alone[1][5][6]. The combination can also be used in other settings where ovarian suppression plus anti-estrogen therapy is indicated.